HANGZHOU TIGERMED CONSULTING (300347) Q3 2024 earnings summary

Executive summary

• Revenue for Q3 2024 was ¥1.71 billion, down 11.87% year-over-year; net profit attributable to shareholders was ¥320.58 million, down 34.74% year-over-year.

• Year-to-date revenue reached ¥5.07 billion, a 10.32% decrease from the same period last year; net profit attributable to shareholders was ¥813.43 million, down 56.72% year-over-year.

• The company completed a major acquisition, increasing its stake in Guanhe Pharma to 72.82%, which will be consolidated into the group’s financials.

Financial highlights

• Operating cash flow for Q3 was ¥578.77 million, down 13.96% year-over-year.

• Basic and diluted EPS for Q3 was ¥0.37, down 35.09% year-over-year; year-to-date EPS was ¥0.94, down 56.68%.

• Total assets at quarter-end were ¥30.28 billion, up 2.01% from year-end 2023.

• Owner’s equity attributable to shareholders was ¥21.06 billion, up 0.18% from year-end 2023.

• Non-recurring gains for Q3 were ¥68.81 million, mainly from investment returns and government subsidies.

Outlook and guidance

• No explicit forward-looking guidance provided, but recent acquisitions and investments indicate a focus on expanding core business and integrating new subsidiaries.